A combination of enfortumab vedotin and pembrolizumab has shown promising results in treating patients with advanced bladder cancer, nearly doubling survival rates compared to chemotherapy. Additionally, Johnson & Johnson’s TAR-200 represents a novel treatment prospect, designed to sustain the local release of chemotherapy drug gemcitabine directly into the bladder. Breakthrough nanotechnology in the form of urea-powered nanorobots has also shown great potential, achieving a 90% reduction in bladder tumor size in a mouse model. These advances indicate a promising future for more targeted, effective, and less invasive bladder cancer treatments.
A division of United Healthcare, Change Healthcare, is dealing with the fallout of a cyber attack. This has heavily impacted the healthcare industry, affecting transactions